27 June, 2007 - TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announces the completion of the acquisition of Apoxis SA.

Consistent with the growth strategy pursued by TopoTarget, the acquisition of the Swiss biotech company Apoxis SA will consolidate two emerging European oncology companies and will achieve the following objectives:

- TopoTarget will have a stronger development pipeline, with the addition of two first-in-class oncology products that have entered clinical development
- Complementary protein chemistry expertise of Apoxis will be added to the existing core competencies in TopoTarget

The two lead oncology products being developed by Apoxis are:

- APO010, a human FAS-ligand protein product generated via Apoxis’ MegaLigandTM proprietary protein technology platform in Phase I clinical development,
- APO866, a small molecule therapeutic that inhibits NAD+ production. APO866 is in three individual Phase II clinical trials


This browser will be redirected to the TopoTarget website in 20 seconds; www.topotarget.com